Literature DB >> 21645174

Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.

A E Elia1, C Dollenz, P Soliveri, A Albanese.   

Abstract

BACKGROUND: Subthalamic nucleus deep brain stimulation (STN DBS) and continuous dopaminergic infusions (jejunal levodopa or subcutaneous apomorphine) are indicated in complicated Parkinson's disease (PD), although it remains unsettled how they compare to each other.
METHODS: We investigated the daytime motor condition in patients with advanced PD under monotherapy with jejunal levodopa, subcutaneous apomorphine, or STN DBS and also measured the motor changes produced by an additional standard morning dose of levodopa. Motor performance was assessed with the UPDRS-III, hand taps, the AIMS dyskinesia score and patients' diaries. Outcome measures were time to best motor 'on' after start of morning treatment, daytime variability of motor condition, motor scores.
RESULTS: The time to 'on' was longest in the jejunal levodopa group. DBS and jejunal levodopa treatments produced stable motor conditions without appreciable 'off' episodes. Continuous apomorphine infusion was associated with the worst motor scores (UPDRS-III and taps) and the most frequent off-states. Jejunal levodopa infusion was associated with the highest AIMS scores. Addition of a levodopa dose produced shortening of time to 'on' and a transient motor improvement in the jejunal levodopa group without increase in dyskinesias; in the DBS and apomorphine groups, there was an increase in dyskinesias without changes in UPDRS-III or taps.
CONCLUSIONS: STN DBS provided adequate trade-off between motor improvement and dyskinesia control, although dyskinesias could be elicited by adding oral levodopa. Jejunal levodopa infusion produced adequate motor improvement with slow time to 'on' and moderate dyskinesias. Apomorphine infusion produced insufficient motor control and negligible dyskinesias.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645174     DOI: 10.1111/j.1468-1331.2011.03437.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

Review 1.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

2.  Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.

Authors:  Christofer Lundqvist; Antonie Giæver Beiske; Ola Reiertsen; Ivar Sønbø Kristiansen
Journal:  J Neurol       Date:  2014-10-01       Impact factor: 4.849

Review 3.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors:  Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

Review 5.  Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review.

Authors:  Iro Boura; Nikolaos Haliasos; Ιrene-Areti Giannopoulou; Dimitrios Karabetsos; Cleanthe Spanaki
Journal:  Mov Disord Clin Pract       Date:  2021-05-19

Review 6.  Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

Authors:  Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky
Journal:  eNeurologicalSci       Date:  2017-07-02

Review 7.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

8.  Au nanoparticle-based sensor for apomorphine detection in plasma.

Authors:  Chiara Zanchi; Andrea Lucotti; Matteo Tommasini; Sebastiano Trusso; Ugo de Grazia; Emilio Ciusani; Paolo M Ossi
Journal:  Beilstein J Nanotechnol       Date:  2015-11-26       Impact factor: 3.649

9.  Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Xiao Dong Liu; Yi Bao; Guang Jian Liu
Journal:  Front Neurol       Date:  2019-08-27       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.